| Literature DB >> 35495577 |
Attila Nemes1, Gergely Rácz1, Árpád Kormányos1, Dóra Földeák2, Zita Borbényi2.
Abstract
Introduction: Amyloidosis is a rare condition due to extracellular deposition of excessive amount of protein in parenchymal tissues including the heart. The present study aimed to test whether cardiac amyloidosis (CA) is associated with morphological and functional abnormalities of the tricuspid annulus (TA). For this aim, the results of patients having CA were compared to age- and gender-matched healthy controls by three-dimensional speckle-tracking echocardiography (3DSTE). Moreover, differences in TA parameters between light-chain CA (AL-CA) and transthyretin CA (TTR-CA) were studies as well. Materials andEntities:
Keywords: Cardiac amyloidosis; Echocardiography; Three-dimensional; Tricuspid annulus
Year: 2022 PMID: 35495577 PMCID: PMC9046960 DOI: 10.1016/j.ijcha.2022.101026
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Fig. 1Extract from a three-dimensional full-volume dataset demonstrating the tricuspid annulus (TA) in a patient with cardiac amyloidosis: apical four-chamber view (A); apical two-chamber view (B); and a cross-sectional view at the level of the tricuspid annulus optimized in apical four- and two-chamber views (C7). The yellow arrow represents the tricuspid annular plane. Abbreviations: LA, left atrium; LV, left ventricle; TA, tricuspid annulus; RA, right atrium; RV, right ventricle; Area, TA area; Circ, TA perimeter; Dist, TA diameter. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Two-dimensional echocardiographic data in patients with cardiac amyloidosis and controls.
| LA diameter (mm) | 40.2 ± 3.6 | 46.1 ± 8.5* |
| LV end-diastolic diameter (mm) | 48.7 ± 3.4 | 46.0 ± 4.7* |
| LV end-diastolic volume (ml) | 111.5 ± 16.8 | 104.1 ± 27.2 |
| LV end-systolic diameter (mm) | 31.5 ± 3.9 | 30.0 ± 5.2 |
| LV end-systolic volume (ml) | 37.0 ± 8.6 | 40.0 ± 17.0 |
| Interventricular septum (mm) | 9.3 ± 1.1 | 15.2 ± 3.7* |
| LV posterior wall (mm) | 9.3 ± 1.0 | 14.0 ± 2.7* |
| LV ejection fraction (%) | 66.9 ± 4.8 | 60.8 ± 13.1 |
| E (cm/s) | 74.9 ± 16.2 | 82.9 ± 22.3 |
| A (cm/s) | 72.7 ± 17.0 | 58.4 ± 29.1 |
| E/A | 0.98 ± 0.4 | 1.92 ± 1.3* |
*p < 0.05 vs. Controls Abbreviations: CA = cardiac amyloidosis, E and A = early and late diastolic transmitral flow velocities, LA = left atrial, LV = left ventricular.
Comparison of three-dimensional speckle-tracking echocardiography-derived tricuspid annular morphological and functional parameters between patients with cardiac amyloidosis and controls.
| TAD-D (cm) | 2.1 ± 0.2 | 3.0 ± 0.6* | 2.9 ± 0.5* | 3.3 ± 0.7* |
| TAA-D (cm2) | 6.1 ± 1.1 | 10.7 ± 3.5* | 10.1 ± 3.3* | 12.8 ± 3.5* |
| TAP-D (cm) | 9.8 ± 1.0 | 12.5 ± 2.0* | 12.2 ± 2.0* | 13.6 ± 1.9* |
| TAD-S (cm) | 1.6 ± 0.2 | 2.6 ± 0.6* | 2.6 ± 0.6* | 2.9 ± 0.8* |
| TAA-S (cm2) | 4.1 ± 1.0 | 8.0 ± 3.2* | 7.5 ± 2.9* | 9.5 ± 3.7* |
| TAP-S (cm) | 8.0 ± 1.0 | 10.6 ± 2.1* | 10.3 ± 1.9* | 11.8 ± 2.4* |
| TAFAC (%) | 32.0 ± 11.1 | 26.1 ± 11.2† | 25.7 ± 10.5† | 27.1 ± 14.3 |
| TAFS (%) | 21.6 ± 7.4 | 12.8 ± 10.3* | 11.9 ± 10.4* | 16.0 ± 9.8 |
Abbreviations: D = end-diastolic, S = end-systolic, CA = cardiac amyloidosis, AL-CA = light-chain cardiac amyloidosis, TTR-CA = transthyretin cardiac amyloidosis, TAD = tricuspid annular diameter, TAA = tricuspid annular area, TAP = tricuspid annular perimeter, TAFAC = tricuspid annular fractional area change, TAFS = tricuspid annular fractional shortening.
*p < 0.05 vs. Controls, †<0.07 vs. Controls.